Sanofi (France)
Parent Company
174/180 Avenue de France
Paris
Cedex
75013
France
Tel: 33-1-53-77-4000
Website: http://www.sanofi-synthelabo.fr/
1707 articles with Sanofi (France)
-
BioSpace Movers and Shakers: Feb. 15
2/15/2019
Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more. -
With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market
2/13/2019
The battle of the bulge is ongoing and it appears that Americans are losing, according to a report from the U.S. Centers for Disease Control and Prevention. The report shows that Americans are losing height and gaining girth. -
As Britain’s plans to leave the European Union—Brexit—stagger toward the March 29 deadline, the UK biopharma industry is taking stock of the likely impact.
-
Sanofi and Regeneron, following Amgen dropping the price of Repatha in October 2018, have dropped Praluent to $5,850 a year. This is about a 60-percent reduction from the original price for both the 75 mg and 150 mg doses. The new prices will kick in early March.
-
The U.S. Food and Drug Administration approved the first treatment for acquired thrombotic thrombocytopenic purpura (aTTP). Sanofi’s Cablivi was given the greenlight and will become a cornerstone of the company’s new rare blood disorders franchise.
-
Thirteen of those were development programs, the remaining 25 research-stage. In September, the company indicated it was on a cost-cutting program, planning to save 1.5 billion euros this year. Of the programs it is dumping, the most prominent is a mid-phase drug for respiratory syncytial virus (...
-
Although bioterrorism doesn’t get the kind of attention more traditional bombings and shootings receive, the biotech industry and the federal government are paying attention and actively funding and developing countermeasures to potential bioterror, military and public health emergencies.
-
Messenger RNA (mRNA) is a family of RNA molecules that transport genetic information from DNA to the ribosome, where it specifies the amino acid sequence that creates proteins. In theory, by coding your own mRNA, it should be possible to insert it into the cells and turn them into protein factori...
-
Over the next two weeks, the U.S. Food and Drug Administration (FDA) has three upcoming decisions. Here’s a look.
-
In October, the Minnesota Attorney General filed a lawsuit against three of the biggest insulin manufacturers over price gouging claims. One month later the American Diabetes Association published recommendations and public policy solutions.
-
Yesterday, the Endocrinologic and Metabolic Drugs Advisory Committee had a split vote, 8 to 8, on whether the overall benefits of Zynquista (sotagliflozin) outweiged the risk in order to support approval. This sends things back to the agency to make a final decision, which has a target action dat...
-
It didn’t take long for the new leadership structure in the U.S. House of Representatives to take on the pharmaceutical industry. On Monday, the House Committee on Oversight and Reform launched an investigation into prescription drug pricing practices.
-
Biotech and pharma companies came roaring out of the gate on the first day of the annual J.P. Morgan Healthcare Conference with big deals, expansions and promises of growth and pipeline sustainability.
-
Tarrytown, NY-based Regeneron Pharmaceuticals and Paris-based Sanofi restructured a 2015 agreement to develop immuno-oncology (I/O) treatments. That deal was scheduled to wrap in 2020, but the revision adds two clinical-stage bispecific antibodies to the collaboration.
-
Days ahead of the J.P. Morgan Healthcare Conference, Germany-based BioNTech extended its three-year-old collaboration with Sanofi as the companies look to co-develop the first cancer immunotherapy candidate for solid tumors.
-
Acer Therapeutics, headquartered in Newton, Mass., in-licensed osanetant, a clinical-stage, selective, non-peptide tachykinin NK3 receptor antagonist from Paris-based Sanofi.
-
For many people France may is synonymous with wines, cheese and rich meals. But the country also has a strong biotech community that how grown significantly over the past decade, with a strong focus on developing clinical drug assets.
-
Readers' Picks: Top 10 Stories of 2018
12/28/2018
As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more. -
The vaccine, Vaxelis, was approved to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenza type b.
-
Paris-based Sanofi announced it was transferring its listing of American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market starting end-of-day December 31, 2018. They will start trading on January 2, 2019.